Interferon Alfa-2a, Recombinant

Tyrosine Kinase Inhibitor

DB00034

Approved Indication

For the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.

2 Targets

0 Resistance Mutations

0 References

3D Structure No structure available

No co-crystal structure available

Protein Targets

IFNAR1 P17181 ✓ IFNAR2 P48551 ✓

Mechanism of Action

Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.

Details

DrugBank ID DB00034 ↗

Approval Date —

Molecular Weight — g/mol

Drug Class Tyrosine Kinase Inhibitor

ATC Codes L03AB04

Synonyms Interferon alfa-2a, Interferon alpha-2a, Interferon-alfa-2a